The evolving landscape of pathology is now digital, generating a wealth of untapped data and creating a new data modality from which life sciences can extract valuable insights. This shift is transformative to accelerate precision medicine drug discovery, development, and ultimately delivery to patients.
Building on 25 years of leading innovation, we are excited to unveil the latest groundbreaking advancements for our Aperio GT 450 Digital Pathology Scanner. The Aperio GT 450 scanner’s proven technology, renowned for performance and reliability, is taken to the next level with scalable, workflow-enhancing features to drive research breakthroughs.
Radboud university medical center (Radboudumc), located in Nijmegen, the Netherlands, is one of the country’s largest academic hospitals. Serving over 175,000 unique patients annually, Radboudumc is a leader in healthcare innovation, research, and education. With a strong focus on prevention, meaningful and prudent healthcare, data-driven systems, and artificial intelligence, Radboudumc is committed to improving patient outcomes while streamlining medical workflows.
As part of its Pathology at Life Speed (PALS) webinar series, Proscia hosted an event earlier this month focused on the promise of foundation models in driving pathology innovation. This session provided a deep dive into one of the largest foundation models for pathology AI development, with practical strategies for data scientists and AI developers to leverage these models for transformative impact on drug discovery and development.
Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, more than doubled its growth in 2024. The company enters 2025 having cemented its leadership position, with life sciences organizations and diagnostic laboratories increasingly deploying its Concentriq® enterprise pathology platform to advance the next novel therapies and diagnostics.
Roche announced today that its whole slide imaging system, Roche Digital Pathology Dx, has received an additional 510(k) clearance from the United States Food and Drug Administration (FDA).
Building AI models for tissue classification in histopathology has traditionally meant assembling large, hand-annotated datasets—a time-consuming and resource-heavy process. But what if you didn’t need those massive datasets? With Concentriq Embeddings and PLIP, a multimodal vision-language foundation model, you can build a zero-shot tissue classification model in minutes—no annotated training data required.
Lumea, a leader in digital pathology solutions, is excited to announce that Cxbladder™, a suite of non-invasive genomic urine tests optimized for the risk stratification and surveillance of urothelial cancer (UC), is now fully integrated into its BxLink™ digital pathology platform. This partnership empowers healthcare providers with streamlined access to Cxbladder’s advanced diagnostic capabilities, further enhancing patient care and clinical efficiency.
Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, has announced that its algorithm for mitotic figure counting has achieved CE marking under the In Vitro Diagnostic Regulation (IVDR) for use in diagnostics. This milestone establishes Aiosyn Mitosis Breast as the first IVDR-certified application for mitosis counting in breast cancer diagnostics and accelerates the company’s growth in clinical pathology.
Leica Biosystems, a global leader in anatomic and digital pathology solutions; and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, today announced that Leica Biosystems has agreed to make a significant strategic investment in Indica Labs. This partnership has the potential to accelerate AI-enabled companion diagnostics (CDx) and support discoveries and treatments based on discrete or complex biomarker expression profiles which are not discernable by the human eye.
